Eric Lefkofsky is trying to find a cure for the medical industry’s problem with how patients’ information is stored and accessed with Tempus. Lefkofsky co-founded the company that created an operating system that is focused on enabling data-driven medicine. Most people don’t ever think about how their medical data is handled until they or a loved one becomes ill, which is exactly what happened when Eric Lefkofsky’s wife was diagnosed with breast cancer. He observed how much information was actually missing or difficult to access that he believed should have been an integral part of his wife’s care.
Not only does Eric Lefkofsky aim to make the data already collected organized and readily available, it also aims to make more currently obscure data like an individual’s complete genetic makeup an orthodox part of patient care. Originally costing more than $100 million when introduced in 2003, the price point has fallen drastically to just around $5,000 and continues to drop thanks to companies like Tempus. Being able to see a patient’s genetic makeup not only makes it easier for doctors and their associates to find treatments suitable for each individual patient, it can also help prevent disease by informing them what they are genetically predisposed to.
Eric Lefkofsky also co-founded Groupon and Lightbank, a company that invests in disruptive technology, along with his work with Tempus. He stepped down from his position of CEO at Groupon to focus on Tempus. Lefkofsky holds the position of adjunct professor at the University of Chicago.
His philanthropic work is as impressive as his success in business. Lefkofsky and his wife created the Lefkofsky Family Foundation in 2006, which is a private charity with the objective to serve those who live in Chicago and surrounding areas. He has also donated millions to various organizations with a focus on cancer research and treatment. Lefkofsky is so focused on giving that he and his wife joined the Giving Pledge and have vowed to donate at least half of their assets to charity within their lifetimes.
Eric Lefkofsky’s Facebook Page: www.facebook.com/eplefkofsky/
Very few things are at the front of Americans’ minds as the threat of cancer. Men, especially, have to worry about prostate cancer when they reach the ages of about 60. However, some men as young as 30 have been known to get this deadly cancer. Luckily, there are ways to stop this cancer from spreading. Mitt Romney recently underwent one of these surgeries in March of 2017 after being diagnosed shortly before. The procedure he underwent was a form of robotic surgery that uses precision and computers to complete the surgery without creating any lasting side effects on the sexual and bladder functions of patients. This new, cutting-edge surgery has helped thousands of men across the globe get rid of the threat without having to threaten their livelihoods and style of living. One of the premier doctors in the field of robotic surgery on prostate cancer is Dr. David Samadi.
Dr. David Samadi is currently the Chairman of Urology and Chief of Robotic Surgery of Urology at Lenox Hill Hospital, located in New York. He has held several posts in robotic surgery and urology throughout his career, and he has used his positions to do vast amounts of research on prostate cancer and coach its victims through the new options available to them.
Several years ago, the only option available to many cancer patients was radiation therapy. This therapy works by essentially poisoning the body, and in turn poisoning and killing the cancer cells. This therapy only helped about 30 percent of cancer victims live another five years. With surgery, however, nearly all of the cancer patients are living much longer lives. The main difference between traditional surgery and robotic surgery is the precision with which the surgeon is able to operate, making the results even more desirable.
Dr. David Samadi has performed over 7,000 of these such procedures. He studied robotic surgery and urology extensively when in school at the Stony Brook School of Medicine at the State University of New York, as well as during his time at the Montefiore Medical Center and Henri Mondor Hospital Creteil located in France. He even had a fellowship at the Memorial Sloan-Kettering Cancer Center. Through all of this experience, Dr. Samadi is able to offer his patients first-rate care with a new and improved system of performing surgery. No matter what, he will continue to give his patients the ability to have a life beyond their cancer and more
Tempus is the latest venture of businessman and philanthropist Eric Lefkofsky. His new venture has managed to secure $70 million dollars in its latest series C venture capitalist funding round. The investors in this latest round include Revolution Growth and New Enterprise Associates.
This latest $70 million dollar cash infusion brings the total number of dollars invested in Tempus to date to $130 million. Tempus is now valued at more than $700 million dollars. It was launched in 2015 by Eric Lefkofsky and a business partner.
Eric Lefkofsky serves as the chief executive officer at Tempus. He has also personally invested considerable funds into Tempus at each funding round. Lefkofsky and his business partner are in fact the single biggest investors in the venture so far. Mr. Lefkofsky has also pledged to invest up to $100 million dollars of his own money into Tempus to see it grow and succeed.
It may seem bizarre that Eric Lefkofsky is now investing in and launching a new healthcare company. After all, he became a billionaire by creating companies and investing in the tech sector and not the healthcare sector. Well, Mr. Lefkofsky has seen a close relative of his afflicted with cancer. He saw the limitations firsthand of the amount of information available regarding cancer treatment. This led him to create Tempus.
So what does Tempus actually aim to do? The company aims to use the latest technology to gather and analyze large amounts of medical data that medical doctors and researchers can then use to treat and study cancer. It is hoped that with more access to information, doctors can then more effectively treat patients with cancer. Eric Lefkofsky has said that the field of oncology or the study of cancer, has historically suffered from a lack of data organization and dissemination. Tempus is looking to change that with its new technology. It also looking to help both doctors and patients that are battling cancer.
To further its goal, Eric Lefkofsky has announced major partnerships with prominent healthcare organizations. They include the Mayo Clinic, The Duke University School of Medicine and the Cleveland Clinic. Together Tempus hopes to build a library of medical data that physicians across the country can use to treat chronic disease such as cancer.
If you want to start a business, you need to have a plan for success. A lot of people have the passion to start a business, but without a plan you will end up with a lot of wasted time and money. Eric Lefkofsky is the type of person who is always willing to take a chance in order to get where he needs to go in life. Not only does he have a track record of success in helping others, but he truly believes in the work that he is doing for his clients. There are a lot of people who are excited about the changes that he is most successful entrepreneurs making to his business. If you want to invest for the future, Eric Lefkofsky is a person to learn from.
From the time that he started his first business, Eric Lefkofsky has always wanted to make an impact on the world. There are a lot of people who look up to his hard work and success in variety of areas. Not only does he truly care about clients, but he wants to help them in a variety of ways as well. There are a lot of people who want to invest for their future in a new business. Not only can this help drive growth, but it can also help you figure out what is best for your future. There are many people who are excited about treatment work that he is doing with his companies.
In the coming years, Eric Lefkofsky wants to help as many clients as possible. Not only can this drive growth for the future, but Eric Lefkofsky wants to make a major impact on the world as well.
A lot of people are excited about the changes that are coming for Eric Lefkofsky and his companies. He knows that he will be able to help others through his work, and that is the passion that keeps him going when things get tough.
To know more visit @: www.bizjournals.com/chicago/news/2016/10/04/groupons-eric-lefkofsky-returns-to-the-forbes-400.html
One of the greatest mysteries that have evading humanity is the mystery of aging. Hundreds of doctors and philosophers have pondered the curiosity that is aging. As technology evolves, more doctors are beginning to understand the aging process on wikipedia.org. Obviously, there’s no cure for aging right now, but there is research supporting the theory that there will be one day. One of the leading researchers on this matter is Mikhail V. Blagosklonny, M.D., Ph.D. Like many before him, Mikhail became fascinated by aging as a young person. There’s clearly an urge in all humans to want to stay young but what evidence supports the reality of that.
Currently, Mikhail Blagosklonny is a professor of oncology at Roswell Park Cancer Institute. Having an interest in medicine and anatomy from a young age, Mikhail has spent much of his adult life in the medical field. He attended the First Pavlov State Medical University of St. Peterburg. He earned both his M.D. and Ph.D. from St. Peterburg. First, he received his M.D. in internal medicine. Second, he received his Ph.D. in experimental medicine and cardiology. After graduating, New York Medical College named him their associate professor of medicine. He held that position for a few years before moving on to being a senior scientist at Ordway Research Institute at https://www.linkedin.com/in/mikhail-blagosklonny-91abb531. It was in 2009 that he accepted his current position at Roswell Park Cancer Institute.
Most of what Mikhail studies are cancer therapies. These kinds of treatments are designed to protect normal, healthy cells from being damaged. In researching cancer therapies, he began studying the fundamental mechanisms of aging. He also studies the anti-aging drugs that pharmaceutical and beauty companies are creating nowadays. Mikhail Blagosklonny keeps track of his studies as editor-in-chief of several science journals. He oversees articles for Aging, Cell Cycle, and Oncotarget. He’s also on the editorial board of a well-known science journal, the Cell Death and Differentiation.
Dr. Mikhail Blagosklonny has written over 200 articles about his researched interests. His peers review all of his articles. Lately, his primary focus has been on cellular biology. He does continue to write about other subjects, such as clinical investigations. What science has learned about aging over the last decade is that it occurs on a cellular level on tandfonline.com. No one can pinpoint why cells age, but there does seem to be a way to slow its aging process.
Decades have passed with a strong push for a cure for cancer, yet despite the amount of money that has been raised for finding a cure, it has never come to fruition. Seattle Genetics, a company that has pioneered antibody-based therapies. These therapies have been heavily researched for the sole purpose of killing cancer cells. While many different drugs have come to the forefront, this time, Seattle Genetics may be the winner.
Seattle Genetics (SGEN) Clay B. Siegall on Q2 2016 Results – Earnings Call Transcript
Additionally, the highlight of this type of therapy is that it is designed to spare those cells that are non-cancerous. The main goal that has been set in order to raise the bar on more holistic therapies, is that chemotherapy would no longer be deemed the first choice for cancer patients. The miracle of meeting unmet needs in the medical field would be an accomplishment, but additionally, it would epitome of medical research as we know it.
These drugs, known as antibody-drug conjugates, or ADC’s, are making headlines as the research and trials continue with the company. This could means that these drugs could potentially become the anti-tumor solution that doctors and patients have been searching for. The treatment level for cancer thus far has included various types of lymphomas include CD30-expressing lymphomas, Hodgkin’s lymphoma, cutaneous T-cell lymphoma, and many others.
Additional trials will also include an ADC that is designed to target various other types of cancers including leukemia, hematologic malignancies, and various types of tumors. The clinical research and trials that are being run by Clay Siegall at